The role of induction chemotherapy for orbital invasion in sinonasal malignancies: A systematic review.
induction chemotherapy
orbital exenteration
orbital invasion
orbital preservation
sinonasal malignancies
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
revised:
16
05
2024
received:
29
03
2024
accepted:
19
05
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
aheadofprint
Résumé
Sinonasal malignancies (SNMs) frequently present with orbital invasion. Orbital exenteration (OE) can lead to significant morbidity. Induction chemotherapy (IC) is a promising treatment alternative that may allow for orbit preserving (OP) treatments without compromising patient survival. This systematic review was conducted to synthesize the published data on SNM patients with orbital invasion who underwent IC, including tumor response, orbital outcomes, and survival. The study protocol was designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Databases Embase, Cochrane, Medline, and Scopus, from inception to July 17, 2023, were searched. Nineteen studies were included, encompassing 305 SNM patients with orbital invasion treated with IC. Fourteen studies reported an overall IC response rate (positive response defined as complete or partial tumor volume reduction) of 77.2%. Among included studies, OE rates after IC ranged from 0 to 40%. Three studies reported a high rate of posttreatment functional orbital preservation (89.8-96.0%). Five studies specifically reported that 62.5% (60 out of 96) of patients were downgraded from planned OE to OP treatment following IC. Three studies reported a significant overall survival (OS) improvement in IC responders versus IC nonresponders. Following IC, 5-year OS ranged from 44.2 to 55.5%. Patients with olfactory neuroblastoma demonstrated the highest IC response rate and lowest OE rate (100 and 0%, respectively) versus those with sinonasal undifferentiated carcinomas (68.4 and 0%) or squamous cell carcinomas (76.7 and 16%). For select patients, IC may allow for OP in locally advanced SNMs with orbital involvement.
Sections du résumé
BACKGROUND
BACKGROUND
Sinonasal malignancies (SNMs) frequently present with orbital invasion. Orbital exenteration (OE) can lead to significant morbidity. Induction chemotherapy (IC) is a promising treatment alternative that may allow for orbit preserving (OP) treatments without compromising patient survival. This systematic review was conducted to synthesize the published data on SNM patients with orbital invasion who underwent IC, including tumor response, orbital outcomes, and survival.
METHODS
METHODS
The study protocol was designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Databases Embase, Cochrane, Medline, and Scopus, from inception to July 17, 2023, were searched.
RESULTS
RESULTS
Nineteen studies were included, encompassing 305 SNM patients with orbital invasion treated with IC. Fourteen studies reported an overall IC response rate (positive response defined as complete or partial tumor volume reduction) of 77.2%. Among included studies, OE rates after IC ranged from 0 to 40%. Three studies reported a high rate of posttreatment functional orbital preservation (89.8-96.0%). Five studies specifically reported that 62.5% (60 out of 96) of patients were downgraded from planned OE to OP treatment following IC. Three studies reported a significant overall survival (OS) improvement in IC responders versus IC nonresponders. Following IC, 5-year OS ranged from 44.2 to 55.5%. Patients with olfactory neuroblastoma demonstrated the highest IC response rate and lowest OE rate (100 and 0%, respectively) versus those with sinonasal undifferentiated carcinomas (68.4 and 0%) or squamous cell carcinomas (76.7 and 16%).
CONCLUSIONS
CONCLUSIONS
For select patients, IC may allow for OP in locally advanced SNMs with orbital involvement.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 ARS‐AAOA, LLC.
Références
Kuan EC, Wang EW, Adappa ND, et al. International consensus statement on allergy and rhinology: sinonasal tumors. Int Forum Allergy Rhinol. 2023. doi:10.1002/alr.23262. Published online September 2,.
Nyirjesy SC, Fenberg R, Heller MA, et al. Response to induction chemotherapy in sinonasal malignancies: a single‐institutional experience. Head Neck. 2023;45(6):1445‐1454. doi:10.1002/hed.27357
Roxbury CR, Ishii M, Richmon JD, Blitz AM, Reh DD, Gallia GL. Endonasal endoscopic surgery in the management of sinonasal and anterior skull base malignancies. Head Neck Pathol. 2016;10(1):13‐22. doi:10.1007/s12105‐016–0687–8
Manjunath L, Derousseau T, Batra PS. Prognostic value of surgical margins during endoscopic resection of paranasal sinus malignancy. Int Forum Allergy Rhinol. 2015;5(5):454‐459. doi:10.1002/alr.21463
Neel GS, Nagel TH, Hoxworth JM, Lal D. Management of orbital involvement in sinonasal and ventral skull base malignancies. Otolaryngol Clin North Am. 2017;50(2):347‐364. doi:10.1016/j.otc.2016.12.010
Patel SG, Singh B, Polluri A, et al. Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer. 2003;98(6):1179‐1187. doi:10.1002/cncr.11630
Howard DJ, Lund VJ, Wei WI. Craniofacial resection for tumors of the nasal cavity and paranasal sinuses: a 25‐year experience. Head Neck. 2006;28(10):867‐873. doi:10.1002/hed.20432
Iannetti G, Valentini V, Rinna C, Ventucci E, Marianetti TM. Ethmoido‐orbital tumors: our experience. J Craniofac Surg. 2005;16(6):1085‐1091. doi:10.1097/01.scs.0000164332.81428.ba
Fleseriu CM, Beswick DM, Maoz SL, et al. Predictive factors for decreased baseline quality of life in patients with sinonasal malignancies. Int Forum Allergy Rhinol. 2023. doi:10.1002/alr.23261. Published online August 30.
Maoz SL, Wang EW, Hwang PH, et al. Long‐term quality of life after treatment in sinonasal malignancy: a prospective, multicenter study. Int Forum Allergy Rhinol. 2023;13(11):2030‐2042. doi:10.1002/alr.23171
Grimm DR, Beswick DM, Maoz SL, et al. SNOT‐22 subdomain outcomes following treatment for sinonasal malignancy: a prospective, multicenter study. Int Forum Allergy Rhinol. 2024. doi:10.1002/alr.23338. Published online February 1.
Amit M, Abdelmeguid AS, Watcherporn T, et al. Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol. 2019;37(6):504‐512. doi:10.1200/JCO.18.00353
Ock CY, Keam B, Kim TM, et al. Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. Korean J Intern Med. 2016;31(3):570‐578. doi:10.3904/kjim.2015.020
Zhao J, Jiang X, Hanna E, et al. Orbital and periocular complications in patients with sinonasal tumours with orbital invasion. Br J Ophthalmol. 2024;108(3):465‐470. doi:10.1136/bjo‐2022‐322855
Carrau RL, Segas J, Nuss DW, et al. Squamous cell carcinoma of the sinonasal tract invading the orbit. Laryngoscope. 1999;109(2):230‐235. doi:10.1097/00005537‐199902000‐00012. Pt 1.
Imola MJ, Schramm VL. Orbital preservation in surgical management of sinonasal malignancy. Laryngoscope. 2002;112(8):1357‐1365. doi:10.1097/00005537‐200208000‐00007. Pt 1.
Turri‐Zanoni M, Lambertoni A, Margherini S, et al. Multidisciplinary treatment algorithm for the management of sinonasal cancers with orbital invasion: a retrospective study. Head Neck. 2019;41(8):2777‐2788. doi:10.1002/hed.25759
Chen N, Yuan H, Fan W, et al. Multimodal treatment with orbital organ preservation in adult patients with locally advanced small‐round‐cell malignancy of the nasal cavity and paranasal sinus. Front Oncol. 2021;11:650385. doi:10.3389/fonc.2021.650385
Kaneko T, Tada Y, Maruya S, et al. Intra‐arterial chemoradiation therapy with weekly low‐dose cisplatin for squamous cell carcinoma of the maxillary sinus. Int J Oral Maxillofac Surg. 2015;44(6):697‐704. doi:10.1016/j.ijom.2015.03.009
Ferrari M, Migliorati S, Tomasoni M, et al. Sinonasal cancer encroaching the orbit: ablation or preservation? Oral Oncol. 2021;114:105185. doi:10.1016/j.oraloncology.2021.105185
Amsbaugh MJ, Yusuf M, Silverman C, et al. Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration. Radiat Oncol J. 2016;34(3):209‐215. doi:10.3857/roj.2016.01739
Patil VM, Joshi A, Noronha V, et al. Neoadjuvant chemotherapy in locally advanced and borderline resectable nonsquamous sinonasal tumors (Esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation). Int J Surg Oncol. 2016;2016:6923730. doi:10.1155/2016/6923730
Resteghini C, Castelnuovo P, Nicolai P, et al. The SINTART 1 study. A phase II non‐randomised controlled trial of induction chemotherapy, surgery, photon‐, proton‐ and carbon ion‐based radiotherapy integration in patients with locally advanced resectable sinonasal tumours. Eur J Cancer. 2023;187:185‐194. doi:10.1016/j.ejca.2023.03.033
Suzuki C, Kishimoto Y, Katagiri T, et al. Induction chemotherapy with paranasal sinus cancer for management of the orbit. Ann Oncol. 2017;28:ix78. doi:10.1093/annonc/mdx697.016
Abdelmeguid AS, Teeramatwanich W, Roberts DB, et al. Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer. 2021;127(11):1788‐1795. doi:10.1002/cncr.33452
Kumar P, Sundriyal D, Bhandari R, Singh A, Jat B, Sehrawat A. Facial disfigurement due to olfactory neuroblastoma: beauty regained with chemotherapy. Cancer Rep (Hoboken). 2021;4(1):e1303. doi:10.1002/cnr2.1303
Bartel R, Gonzalez‐Compta X, Cisa E, et al. Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: series report and literature review. Acta Otorrinolaringol Esp (Engl Ed). 2018;69(4):208‐213. doi:10.1016/j.otorri.2017.07.001
Su SY, Bell D, Ferrarotto R, et al. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017;39(8):1671‐1679. doi:10.1002/hed.24822
Lin EM, Sparano A, Spalding A, et al. Sinonasal undifferentiated carcinoma: a 13‐year experience at a single institution. Skull Base. 2010;20(2):61‐67. doi:10.1055/s‐0029‐1236165
Xu CC, Dziegielewski PT, McGaw WT, Seikaly H. Sinonasal undifferentiated carcinoma (SNUC): the Alberta experience and literature review. J Otolaryngol Head Neck Surg. 2013;42(1):2. doi:10.1186/1916‐0216–42‐2
Wang L, Wang J, Tang T, Yan L, Song X. Definitive‐intent (chemo)radiotherapy for sinonasal undifferentiated carcinoma. Br J Radiol. 2023;96(1141):20220244. doi:10.1259/bjr.20220244
Kuo YH, Lin CS. Regression of advanced maxillary sinus cancer with orbital invasion by combined chemotherapy and immunotherapy: a one‐year follow‐up case report. Mol Clin Oncol. 2022;16(4):94. doi:10.3892/mco.2022.2527
Lilly G, Geltzeiler M. Induction chemotherapy for orbit preservation in sinonasal squamous cell carcinoma. J Neurol Surg Rep. 2021;82(3):e36‐e37. doi:10.1055/s‐0041‐1736160
Parbhu KC, Galler KE, Murphy BA, Pitchford CW, Mawn LA. Primary ocular presentation of sinonasal undifferentiated carcinoma. Ophthalmic Plast Reconstr Surg. 2010;26(1):61‐63. doi:10.1097/IOP.0b013e3181b8c6db
Suparmaniam S, Ngoo QZ, Wan Hitam WH, Moknasing @ John PA. Sinonasal lymphoepithelial carcinoma with aggressive orbital invasion. Cureus;14(11):e31103. doi:10.7759/cureus.31103
Watanabe S, Honma Y, Murakami N, et al. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: two cases of report. World J Clin Cases. 2019;7(6):765‐772. doi:10.12998/wjcc.v7.i6.765
Yamaoka M, Akiyama M, Yokokawa Y, et al. Multidisciplinary therapy including proton beam radiotherapy for a Ewing sarcoma family tumor of maxillary sinus in a 4‐year‐old girl. Head Neck. 2013;35(12):E386‐390. doi:10.1002/hed.23352